# Enhancing ICB Efficacy Through IL-1 Inhibition in TNBC

> **NCT07698106** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **University Health Network, Toronto** · enrollment: 60 (estimated)

## Conditions studied

- Triple-Negative Breast Cancer (TNBC)

## Interventions

- **DRUG:** Group 1-Isunakinra

## Key facts

- **NCT ID:** NCT07698106
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10
- **Primary completion:** 2034-08
- **Final completion:** 2034-08
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-09-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07698106

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07698106, "Enhancing ICB Efficacy Through IL-1 Inhibition in TNBC". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07698106. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*